CardiovascularINJECTIONGeneric
ABELCET
AMPHOTERICIN B
Standard Dose
5MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Key Takeaways
- Primary indication: Review priority: PRIORITY Marketing status: Discontinued
- Approval overview ABELCET is listed in Drugs@FDA under application 050724 (NDA).
- Review priority: PRIORITY Marketing status: Discontinued Active ingredient AMPHOTERICIN B Form and strength INJECTABLE, LIPID COMPLEX;INJECTION - 5MG/ML Sponsor LEADIANT BIOSCI INC Submission history Latest submission status date: 2013-12-23 00:00:00.
Structured Monograph
Clinical summary
Approval overview ABELCET is listed in Drugs@FDA under application 050724 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient AMPHOTERICIN B Form and strength INJECTABLE, LIPID COMPLEX;INJECTION - 5MG/ML Sponsor LEADIANT BIOSCI INC Submission history Latest submission status date: 2013-12-23 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.